TY - JOUR
T1 - Survival Trends in Young Patients With Multiple Myeloma
T2 - A Focus on Racial-Ethnic Minorities
AU - Ailawadhi, Sikander
AU - Azzouqa, Abdel Ghani
AU - Hodge, David
AU - Cochuyt, Jordan
AU - Jani, Prachi
AU - Ahmed, Salman
AU - Sher, Taimur
AU - Roy, Vivek
AU - Ailawadhi, Meghna
AU - Alegria, Victoria R.
AU - Manochakian, Rami
AU - Vishnu, Prakash
AU - Grover, Ashna
AU - Abdulazeez, Mays F.
AU - Paulus, Aneel
AU - Chanan-Khan, Asher
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/10
Y1 - 2019/10
N2 - Introduction: Outcomes in multiple myeloma (MM) have improved significantly over time. This is true overall for all patients as well as patient subgroups based on age and race/ethnicity. Despite this, disparities are noted in outcomes when looking at racial subgroups. Materials and Methods: We performed an analysis from the population-based Surveillance, Epidemiology, and End Results (SEER) database to evaluate improvement in relative survival rates (RSRs) for young (≤ 40 years at the time of MM diagnosis) and older (> 40 years at the time of MM diagnosis) over time by race/ethnicity, specifically focusing on Hispanic patients with MM. Expected survival was estimated using the age- and gender-specific death rates from the United States population. RSR was provided as the ratio of the observed to expected survival at individual time points. Five-year and 10-year RSRs were calculated for patients based on treatments modalities available in various time periods. Results: We identified a total of 89,451 patients with MM in SEER, of which 1460 patients formed the young patients with MM (≤ 40 years) cohort. Five- and 10-year RSR improved significantly over time for all patients and older patients (> 40 years) by race (all P < .001). Evaluating the younger patients, RSR improved significantly for non-Hispanic whites and non-Hispanic blacks, but not for Hispanics. This was true for the 5-year (P = .08) and 10-year (P = .13) RSRs. Conclusion: We report a lack of significant benefit in long-term outcomes for younger Hispanic patients with MM over time. This could be owing to multifactorial causes that need to be addressed to mitigate outcome disparities.
AB - Introduction: Outcomes in multiple myeloma (MM) have improved significantly over time. This is true overall for all patients as well as patient subgroups based on age and race/ethnicity. Despite this, disparities are noted in outcomes when looking at racial subgroups. Materials and Methods: We performed an analysis from the population-based Surveillance, Epidemiology, and End Results (SEER) database to evaluate improvement in relative survival rates (RSRs) for young (≤ 40 years at the time of MM diagnosis) and older (> 40 years at the time of MM diagnosis) over time by race/ethnicity, specifically focusing on Hispanic patients with MM. Expected survival was estimated using the age- and gender-specific death rates from the United States population. RSR was provided as the ratio of the observed to expected survival at individual time points. Five-year and 10-year RSRs were calculated for patients based on treatments modalities available in various time periods. Results: We identified a total of 89,451 patients with MM in SEER, of which 1460 patients formed the young patients with MM (≤ 40 years) cohort. Five- and 10-year RSR improved significantly over time for all patients and older patients (> 40 years) by race (all P < .001). Evaluating the younger patients, RSR improved significantly for non-Hispanic whites and non-Hispanic blacks, but not for Hispanics. This was true for the 5-year (P = .08) and 10-year (P = .13) RSRs. Conclusion: We report a lack of significant benefit in long-term outcomes for younger Hispanic patients with MM over time. This could be owing to multifactorial causes that need to be addressed to mitigate outcome disparities.
KW - Age-related survival
KW - Disparity
KW - Inequity in healthcare
KW - Outcomes
KW - Time-related trend
UR - http://www.scopus.com/inward/record.url?scp=85069907159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069907159&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2019.06.010
DO - 10.1016/j.clml.2019.06.010
M3 - Article
C2 - 31377212
AN - SCOPUS:85069907159
SN - 2152-2650
VL - 19
SP - 619
EP - 623
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 10
ER -